Electrical Vestibular Nerve Stimulation (VeNS) Compared to Sham Control As a Means of Improving Glycemic Control in Adults with Type 2 Diabetes Mellitus

NACompletedINTERVENTIONAL
Enrollment

267

Participants

Timeline

Start Date

May 21, 2021

Primary Completion Date

August 6, 2024

Study Completion Date

August 6, 2024

Conditions
Type 2 Diabetes
Interventions
DEVICE

Vestal DM Active device

Battery powered non-invasive neurostimulation device

BEHAVIORAL

Lifestyle modification

Subjects are prescribed a low calorie (500kcal deficit) diet if their BMI is ≥25. If a subject has a BMI of ≤24.9, they will be provided with guidance on ensuring their recommended daily dietary intake is achieved throughout the course of the trial (i.e 2,500kcal/day for men and 2,000kcal/day for women)

DEVICE

Vestal DM Sham device

Placebo comparator sham device (no active stimulation)

Trial Locations (16)

10029

Icahn School of Medicine at Mount Sinai, New York

22911

Charlottesville Medical Research Center, Charlottesville

32757

Adult Medicine of Lake County, Mt. Dora

32765

Oviedo Medical Research, Oviedo

33020

New Med Research, Hollywood

33166

South Florida Research Organization, Medley

35294

University of Alabama, Birmingham

37209

Complete Health Partners, Nashville

59101

Billings Clinic, Billings

78503

Biopharma Informatic, McAllen

89148

Palm Research Center, Las Vegas

92093

UC San Diego, Exercise and Physical Activity Resource Center, La Jolla

95821

Northern California Research, Sacramento

01844

ActivMed Practices & Research, Methuen

03801

ActivMed Practices & Research, Portsmouth

D04 T6F4

St. Vincent's University Hospital, Dublin

Sponsors
All Listed Sponsors
collaborator

University College Dublin

OTHER

collaborator

CS Lifescience

UNKNOWN

collaborator

Clinical Trial Mentors

INDUSTRY

lead

Neurovalens Ltd.

INDUSTRY